Zobrazeno 1 - 10
of 360
pro vyhledávání: '"Francine M. Foss"'
Autor:
Amber Loren O. King, BA, Fatima N. Mirza, MPH, Julia M. Lewis, PhD, Kacie R. Carlson, PA, Scott Huntington, MD, MPH, Francine M. Foss, MD, Michael Girardi, MD
Publikováno v:
JAAD Case Reports, Vol 8, Iss , Pp 89-92 (2021)
Externí odkaz:
https://doaj.org/article/e9d5715a259b49d2a1c86d37aa482b0b
Autor:
Patrick B. Johnston, Amanda F. Cashen, Petros G. Nikolinakos, Anne W. Beaven, Stefan Klaus Barta, Gajanan Bhat, Steven J. Hasal, Sven De Vos, Yasuhiro Oki, Changchun Deng, Francine M. Foss
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-11 (2021)
Abstract Background Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belinostat combined with CH
Externí odkaz:
https://doaj.org/article/af527152ded04cb9a0629860f5f6b4cf
Autor:
Amanda Zhou, BS, William Damsky, MD, PhD, Michael Girardi, MD, Francine M. Foss, MD, Matthew D. Vesely, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 11, Iss , Pp 10-12 (2021)
Externí odkaz:
https://doaj.org/article/3416e86a4b0243f193360ef95d675a7b
Autor:
Savanah D. Gisriel, Kenneth W. Hung, Demetrios T. Braddock, Stuart Seropian, Francine M. Foss, Marie E. Robert, Mina L. Xu
Publikováno v:
Human Pathology: Case Reports, Vol 24, Iss , Pp 200507- (2021)
Cutaneous T-cell lymphoma (CTCL) presenting as mycosis fungoides is typically localized to the skin and occasional draining lymph nodes. We present a 46-year-old man with refractory CTCL status-post allogeneic stem cell transplant who was biopsied fo
Externí odkaz:
https://doaj.org/article/89ddd6eac26d4a49a62399c3a4599210
Autor:
Monica Bellei, Francine M. Foss, Andrei R. Shustov, Steven M. Horwitz, Luigi Marcheselli, Won Seog Kim, Maria E. Cabrera, Ivan Dlouhy, Arnon Nagler, Ranjana H. Advani, Emanuela A. Pesce, Young-Hyeh Ko, Virginia Martinez, Silvia Montoto, Carlos Chiattone, Alison Moskowitz, Michele Spina, Irene Biasoli, Martina Manni, Massimo Federico
Publikováno v:
Haematologica, Vol 103, Iss 7 (2018)
This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed diseas
Externí odkaz:
https://doaj.org/article/79f7373acd4c4f49a3efc28c780ef628
Autor:
Massimo Federico, Monica Bellei, Emanuela Pesce, Emanuele Zucca, Stefano Pileri, Silvia Montoto, Dennis D Weisenburger, Thomas Ruediger, Y. H. Ko., Raymond Liang, Pier L. Zinzani, Joseph M. Connors, Francine M. Foss, Steven M. Horwitz, Aaron Polliack, Julie M. Vose
Publikováno v:
Revista Brasileira de Hematologia e Hemoterapia, Vol 31, Pp 21-25 (2009)
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation and with different morphological patterns, phenotypes, and clinical presentations.
Externí odkaz:
https://doaj.org/article/5ff6b7c72116475b904925864167ca6b
Autor:
Arthur E. Frankel, Jung H. Woo, Chul Ahn, Francine M. Foss, Madeleine Duvic, Paul H. Neville, David M. Neville
Publikováno v:
Haematologica, Vol 100, Iss 6 (2015)
Resimmune is a second-generation recombinant immunotoxin composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain antibody fragments reactive with the extracellular domain of CD3ε. We gave intravenous infusio
Externí odkaz:
https://doaj.org/article/0972f4de5f714610a05a9176e0a03c08
Autor:
Kunal C. Potnis, Mengyang Di, Iris Isufi, Lohith Gowda, Stuart E. Seropian, Francine M. Foss, Howard P. Forman, Scott F. Huntington
Publikováno v:
Blood Advances. 7:801-810
Follicular lymphoma (FL) is traditionally considered treatable but incurable. In March 2021, the US Food and Drug Administration approved the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) FL after
Autor:
Julio C. Chavez, Francine M. Foss, Basem M. William, Jonathan E. Brammer, Sonali M. Smith, Anca Prica, Jasmine M. Zain, Joseph M. Tuscano, Harsh Shah, Neha Mehta-Shah, Praveen Ramakrishnan Geethakumari, Ben X. Wang, Stephanie Zantinge, Lisa Wang, Ling Zhang, Anmarie Boutrin, Weiguang Zhao, Lily Cheng, Nathan Standifer, Lisa Hewitt, Enowmpey Enowtambong, Weiping Shao, Shringi Sharma, Gianluca Carlesso, Jeffrey A. Moscow, Lillian L. Siu
Publikováno v:
Clinical Cancer Research. 29:1869-1878
Purpose: Proliferation of T-follicular helper (TFH) CD4+ T cells is a postulated pathogenic mechanism for T-cell non-Hodgkin lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by TFH, representing a potential target. MEDI
Autor:
Lillian L. Siu, Jeffrey A. Moscow, Gianluca Carlesso, Shringi Sharma, Weiping Shao, Enowmpey Enowtambong, Lisa Hewitt, Nathan Standifer, Lily Cheng, Weiguang Zhao, Anmarie Boutrin, Ling Zhang, Lisa Wang, Stephanie Zantinge, Ben X. Wang, Praveen Ramakrishnan Geethakumari, Neha Mehta-Shah, Harsh Shah, Joseph M. Tuscano, Jasmine M. Zain, Anca Prica, Sonali M. Smith, Jonathan E. Brammer, Basem M. William, Francine M. Foss, Julio C. Chavez
Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d3ce24c1e2410c2dc54c60bc33a6ba1
https://doi.org/10.1158/1078-0432.22820146.v1
https://doi.org/10.1158/1078-0432.22820146.v1